Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clemens Oliver Hanemann

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Brain Pathology (Zurich, Switzerland)|January 24, 2014
Schwannomas and their pathogenesisDavid A Hilton, Clemens Oliver Hanemann
Journal of Neuropathology and Experimental Neurology|July 11, 2007
Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomasChristine Flaiz, Katherine Kaempchen, Cordula Matthies, et al.
Neuro-Oncology|July 6, 2011
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2Sylwia Ammoun, Marei Caroline Schmid, Joceline Triner, et al.
Cancer|April 4, 2003
Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cellsTamara Utermark, Alexi Alekov, Holger Lerche, et al.
Molecular Oncology|September 14, 2014
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumoursSylwia Ammoun, Marei Caroline Schmid, Lu Zhou, et al.
Brain : a Journal of Neurology|March 5, 2003
A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier diseaseStephan Züchner, Anne D Sperfeld, Jan Senderek, et al.
Neoplasia (New York, N.Y.)|January 17, 2012
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathwaysLu Zhou, Emanuela Ercolano, Sylwia Ammoun, et al.
Journal of Neuro-Oncology|September 8, 2022
miR-497 and 219 in blood aid meningioma classificationAhmed Abdelrahman, Caterina Negroni, Felix Sahm, et al.
Ebiomedicine|June 25, 2025
Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomasMaryam Shah, Yeasmin Akther, Claire L Adams, et al.
Neuro-Oncology|January 17, 2019
Molecular and translational advances in meningiomasSuganth Suppiah, Farshad Nassiri, Wenya Linda Bi, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Brain Pathology (Zurich, Switzerland)|January 24, 2014
Schwannomas and their pathogenesisDavid A Hilton, Clemens Oliver Hanemann
Journal of Neuropathology and Experimental Neurology|July 11, 2007
Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomasChristine Flaiz, Katherine Kaempchen, Cordula Matthies, et al.
Neuro-Oncology|July 6, 2011
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2Sylwia Ammoun, Marei Caroline Schmid, Joceline Triner, et al.
Cancer|April 4, 2003
Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cellsTamara Utermark, Alexi Alekov, Holger Lerche, et al.
Molecular Oncology|September 14, 2014
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumoursSylwia Ammoun, Marei Caroline Schmid, Lu Zhou, et al.
Brain : a Journal of Neurology|March 5, 2003
A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier diseaseStephan Züchner, Anne D Sperfeld, Jan Senderek, et al.
Neoplasia (New York, N.Y.)|January 17, 2012
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathwaysLu Zhou, Emanuela Ercolano, Sylwia Ammoun, et al.
Journal of Neuro-Oncology|September 8, 2022
miR-497 and 219 in blood aid meningioma classificationAhmed Abdelrahman, Caterina Negroni, Felix Sahm, et al.
Ebiomedicine|June 25, 2025
Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomasMaryam Shah, Yeasmin Akther, Claire L Adams, et al.
Neuro-Oncology|January 17, 2019
Molecular and translational advances in meningiomasSuganth Suppiah, Farshad Nassiri, Wenya Linda Bi, et al.
Pageof 2